IQV vs MEDP stock comparison
Iqvia vs. Medpace · data as of November 13, 2026
Iqvia (IQV) has a market value of about $43.7B, Medpace (MEDP) about $18.3B. Over their latest twelve months Iqvia had revenue of $17.3B and Medpace $2.8B.
On our five checks Medpace scores higher: 3.2 out of 5 (average) against 1.6 (weak).
By area, the stronger company is Medpace on future growth; Medpace on track record; Medpace on financial health; Iqvia on shareholder returns.
Iqvia is cheaper on earnings (P/E 32.3 vs. 36.3), while Medpace grew revenue faster over five years (22.3% vs. 7.5% a year).
Iqvia leads on 12 of the compared lines and Medpace on 9.
Side by side
| IQV | MEDP | |
|---|---|---|
| Size and price | ||
| Market cap | $43.7B | $18.3B |
| Share price | $265.12 | $653.94 |
| Score | ||
| Overall score (of 5) | 1.6 | 3.2 |
| Value | 1 | 1 |
| Future growth | 0 | 4 |
| Track record | 3 | 5 |
| Financial health | 1 | 4 |
| Shareholder returns | 3 | 2 |
| Valuation | ||
| P/E (TTM) | 32.3 | 36.3 |
| Forward P/E | 19.2 | 33.6 |
| Price / free cash flow | 21.0 | 27.4 |
| Price / sales | 2.5 | 6.4 |
| EV / EBITDA | 16.8 | 27.9 |
| PEG | 0.80 | 1.14 |
| DCF value vs. price | −24% | −32% |
| Business | ||
| Revenue | $17.3B | $2.8B |
| Net income | $1.4B | $518M |
| Free cash flow | $2.1B | $668M |
| Net margin | 8.1% | 18.2% |
| Gross margin (5-yr avg.) | — | — |
| ROIC (5-yr avg.) | 8.0% | 41.9% |
| Growth | ||
| Revenue growth (1 yr) | 5.9% | 20.0% |
| Revenue growth (5 yrs, per year) | 7.5% | 22.3% |
| EPS growth (5 yrs, per year) | 40.5% | 31.8% |
| Balance sheet and payouts | ||
| Net cash (cash minus debt) | -$14.0B | — |
| Dividend yield | None | None |
| Shareholder yield | 2.9% | 5.0% |
| Analysts | ||
| Upside to average target | +18% | −0% |
| Consensus rating | Strong buy | none |
Highlighted = the better figure on that line. Revenue, net income and free cash flow: IQV TTM to September 30, 2026, MEDP TTM to September 30, 2026. Not investment advice.
Frequently asked questions
Which is the better stock, Iqvia or Medpace?
We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Medpace scores 3.2 out of 5 and Iqvia 1.6; the table shows where each one is stronger.
Is Iqvia cheaper than Medpace?
On trailing earnings, Iqvia trades at a P/E of 32.3 and Medpace at 36.3, so Iqvia is cheaper by this measure. A lower P/E can also reflect slower expected growth.
Which grows faster, Iqvia or Medpace?
Over five years Medpace grew revenue about 22.3% a year and Iqvia about 7.5% a year.
Full Iqvia analysis → Full Medpace analysis →
More comparisons
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.